Two other clinical trials showed that exenatide as an add-on to standard insulin therapy in patients with T1DM did not significantly reduce HbA1c, glycemic excursions, or glycemic variability compared with placebo when used either as a short-acting drug three times daily or as an extended release once weekly [8,9]. The gene discussed is INS; the disease is type 1 diabetes mellitus.